Dec. 3, 2015, 7:29 PM
- Specialty pharmaceutical firm Egalet (EGLT -2.6%) says it's terminating a collaboration with Shionogi Limited (OTCPK:SGIOY) around an abuse-deterrent, extended-release hydrocodone candidate.
- The move ends a two-year relationship and means Egalet gains worldwide rights to the Phase 1 product candidate.
- The deal had means upfront and milestone payments totaling $20M and an investment of $15M in its stock connected to its 2014 IPO. Egalet says it terminated the deal "with the change in [Shinogi's] internal priorities."
Currently, there's no company description for SGIOF.
Industry: Drug Related Products
Other News & PR